PT - JOURNAL ARTICLE AU - Ujjainiya, Rajat AU - Tyagi, Akansha AU - Sardana, Viren AU - Naushin, Salwa AU - Bhatheja, Nitin AU - Kumar, Kartik AU - Barman, Joydeb AU - Prakash, Satyartha AU - Kutum, Rintu AU - Bhaskar, Akash K AU - Singh, Prateek AU - Chaudhary, Kumardeep AU - Loomba, Menka AU - Khanna, Yukti AU - Walecha, Chestha AU - Ahmed, Rizwan AU - Yadav, Ashutosh AU - Bajaj, Archana AU - Malik, Gaurav AU - Qureshi, Sahar AU - Waghdhare, Swati AU - Siddiqui, Samreen AU - Trehan, Kamal Krishan AU - Mani, Manju AU - Dang, Rajiv AU - Das, Poonam AU - Dougall, Pankaj AU - Mahajan, Monica AU - Sonar, Sudipta AU - Jakhar, Kamini AU - Kumar, Reema AU - Tiwari, Mahima AU - Mani, Shailendra AU - Bhattacharyya, Sankar AU - Budhiraja, Sandeep AU - Agrawal, Anurag AU - Dash, Debasis AU - Jha, Sujeet AU - Sengupta, Shantanu TI - High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge: a case for continued use of masks post-vaccination AID - 10.1101/2021.02.28.21252621 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.28.21252621 4099 - http://medrxiv.org/content/early/2021/08/28/2021.02.28.21252621.short 4100 - http://medrxiv.org/content/early/2021/08/28/2021.02.28.21252621.full AB - Immunization is expected to confer protection against infection and severe disease for vaccinees, while reducing risks to unimmunized populations by inhibiting transmission. Here, based on serial serological studies, we show that during a severe SARS-CoV2 Delta-variant outbreak in Delhi, 25.3% (95% CI 16.9 - 35.2) of previously uninfected, ChAdOx1-nCoV19 double vaccinated, healthcare-workers (HCW) were infected within a period of less than two months, based on serology. Induction of anti-spike response was similar between groups with breakthrough infection (541 U/ml, IQR 374) or not (342 U/ml, IQR 497), as was induction of neutralization activity to wildtype. Most infections were unrecognized. The Delta-variant thus causes frequent unrecognized breakthrough infections in adequately immunized subjects, reducing any herd-effect of immunity, and requiring reinstatement of preventive measures such as masking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Ethics Committee (Max healthcare Committee), New Delhi with separate approval for all sites and CSIR-IGIB, New Delhi IHECAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for de-identified data may be send to the corresponding authors stating end usage. Data will be shared on request basis.